Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GREM1 antisense RNA 1 (GREM1-AS1) is a long non-coding RNA gene transcribed as an antisense strand relative to the GREM1 (Gremlin 1) gene locus[4]. As an antisense lncRNA, GREM1-AS1 is part of a class of RNAs that typically regulate gene expression by mechanisms such as transcriptional interference, chromatin remodeling, or modulating RNA processing[3][5]. While antisense RNAs are known to impact gene regulation both in cis and trans, detailed functional insights specific to GREM1-AS1 are currently lacking in authoritative databases and literature. There is no evidence that GREM1-AS1 is a therapeutic target or that it interacts with approved drugs, nor are there established clinical biomarkers or safety concerns associated with its modulation. GREM1-AS1 is a valid antisense lncRNA with limited characterization. It is not a conventional therapeutic target (such as a receptor or enzyme), and little is known about its precise biological or disease roles. No drugs, biomarkers, or safety concerns are associated with this RNA to date[4][5][3].
Not applicable; no validated drugs or antisense oligonucleotides are documented to modulate GREM1-AS1 specifically.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GREM1 antisense RNA 1 (GREM1-AS1).